S&P 500   3,829.34 (-2.45%)
DOW   31,402.01 (-1.75%)
QQQ   312.89 (-3.47%)
AAPL   120.99 (-3.48%)
MSFT   229.70 (-2.07%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   687.90 (-7.29%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.15 (-6.88%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.21 (-5.44%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
S&P 500   3,829.34 (-2.45%)
DOW   31,402.01 (-1.75%)
QQQ   312.89 (-3.47%)
AAPL   120.99 (-3.48%)
MSFT   229.70 (-2.07%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   687.90 (-7.29%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.15 (-6.88%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.21 (-5.44%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
S&P 500   3,829.34 (-2.45%)
DOW   31,402.01 (-1.75%)
QQQ   312.89 (-3.47%)
AAPL   120.99 (-3.48%)
MSFT   229.70 (-2.07%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   687.90 (-7.29%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.15 (-6.88%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.21 (-5.44%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
S&P 500   3,829.34 (-2.45%)
DOW   31,402.01 (-1.75%)
QQQ   312.89 (-3.47%)
AAPL   120.99 (-3.48%)
MSFT   229.70 (-2.07%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   687.90 (-7.29%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.15 (-6.88%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.21 (-5.44%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
Log in
NASDAQ:AVRO

AVROBIO Stock Forecast, Price & News

$10.98
-0.04 (-0.36 %)
(As of 02/25/2021 03:59 PM ET)
Add
Compare
Today's Range
$10.57
Now: $10.98▼
$11.28
50-Day Range
$11.09
MA: $14.73▼
$19.30
52-Week Range
$9.76
Now: $10.98▼
$23.50
Volume102,819 shs
Average Volume602,926 shs
Market Capitalization$400.23 million
P/E RatioN/A
Dividend YieldN/A
Beta1.41
AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company has a research and clinical collaboration agreement with Magenta Therapeutics to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. AVROBIO, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
AVROBIO logo

Headlines

AVROBIO to Present at Three Upcoming Investor Conferences in March
February 25, 2021 |  finance.yahoo.com
Avrobio: An Update After Stock Price Drop After bluebird Trial Halt - Seeking Alpha
February 17, 2021 |  seekingalpha.com
bluebird bio trial suspension hurts Orchard and AVROBIO - Seeking Alpha
February 16, 2021 |  seekingalpha.com
Why Avrobio's Stock is Up During Today's Session - Benzinga
February 8, 2021 |  benzinga.com
AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial
February 8, 2021 |  finance.yahoo.com
Avrobio Shares Rally On Fabry Disease Gene Therapy Encouraging Benefit In Early-Stage Study
February 8, 2021 |  finance.yahoo.com
AVROBIO Announces Multiple Clinical Data Presentations, Posters and Events at 17th Annual WORLDSymposium™ 2021 - Business Wire
February 1, 2021 |  businesswire.com
AVROBIO Announces Multiple Clinical Data Presentations, Posters and Events at 17th Annual WORLDSymposium™ 2021
February 1, 2021 |  finance.yahoo.com
Biotech Showcase™ Digital Extends On-Demand Access to This Year’s Sessions, Content and Company Presentations Through March 2021 - Yahoo Finance
January 22, 2021 |  finance.yahoo.com
AVROBIO to Present at the Cowen 2021 Gene Therapy: CMC & Regulatory Summit
January 22, 2021 |  finance.yahoo.com
AVROBIO Announces the Appointment of Diana M. Escolar, M.D. as Chief Medical Officer - Business Wire
January 19, 2021 |  businesswire.com
AVROBIO Announces the Appointment of Diana M. Escolar, M.D. as Chief Medical Officer
January 19, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AVRO
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.avrobio.com
Phone617-914-8420
Employees123
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio9.14
Quick Ratio9.14

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$5.87 per share
Price / Book1.87

Profitability

EPS (Most Recent Fiscal Year)($2.66)
Net Income$-72,960,000.00
Net MarginsN/A
Return on Equity-51.33%
Return on Assets-47.65%

Miscellaneous

Outstanding Shares36,451,000
Market Cap$400.23 million
Next Earnings Date3/15/2021 (Estimated)
OptionableNot Optionable

MarketRank™

Overall MarketRank™

1.67 out of 5 stars

Medical Sector

244th out of 1,957 stocks

Biological Products, Except Diagnostic Industry

28th out of 177 stocks

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$10.98
-0.04 (-0.36 %)
(As of 02/25/2021 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVRO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AVROBIO (NASDAQ:AVRO) Frequently Asked Questions

Is AVROBIO a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVROBIO stock.
View analyst ratings for AVROBIO or view top-rated stocks.

What stocks does MarketBeat like better than AVROBIO?

Wall Street analysts have given AVROBIO a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AVROBIO wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting AVROBIO?

AVROBIO saw a decrease in short interest in January. As of January 15th, there was short interest totaling 2,770,000 shares, a decrease of 22.0% from the December 31st total of 3,550,000 shares. Based on an average daily volume of 331,800 shares, the days-to-cover ratio is presently 8.3 days.
View AVROBIO's Short Interest.

When is AVROBIO's next earnings date?

AVROBIO is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for AVROBIO.

How were AVROBIO's earnings last quarter?

AVROBIO, Inc. (NASDAQ:AVRO) posted its quarterly earnings data on Tuesday, November, 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.81) by $0.20.
View AVROBIO's earnings history.

How has AVROBIO's stock been impacted by COVID-19 (Coronavirus)?

AVROBIO's stock was trading at $18.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AVRO shares have decreased by 39.1% and is now trading at $10.98.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for AVRO?

7 equities research analysts have issued 12 month target prices for AVROBIO's shares. Their forecasts range from $13.00 to $43.00. On average, they anticipate AVROBIO's share price to reach $30.60 in the next twelve months. This suggests a possible upside of 178.7% from the stock's current price.
View analysts' price targets for AVROBIO or view top-rated stocks among Wall Street analysts.

Who are AVROBIO's key executives?

AVROBIO's management team includes the following people:
  • Mr. Geoff MacKay, Co- Founder, Pres, CEO & Director (Age 55, Pay $746.7k)
  • Mr. Erik Ostrowski M.B.A., CFO & Treasurer (Age 48, Pay $739.58k)
  • Mr. Steven N. Avruch J.D., Chief Legal Officer & Sec. (Age 60, Pay $441.68k)
  • Mr. Jeffrey Medin Ph.D., Scientific Founder
  • Mr. Matthew Arnold, Head of Operations
  • Mr. Kim Raineri M.B.A., Chief Manufacturing & Technology Officer
  • Dr. Christopher Mason, Chief Scientific Officer (Age 62)
  • Ms. Monique Da Silva, Sr. VP of Corp. Communications
  • Ms. Georgette Verdin, Chief HR Officer
  • Ms. Deanna M. Petersen M.B.A., MBA, Chief Bus. Officer (Age 59)

Who are some of AVROBIO's key competitors?

Some companies that are related to AVROBIO include Krystal Biotech (KRYS), REGENXBIO (RGNX), Alector (ALEC), Atara Biotherapeutics (ATRA), Vaxcyte (PCVX), Adverum Biotechnologies (ADVM), Coherus BioSciences (CHRS), Mesoblast (MESO), Taysha Gene Therapies (TSHA), Inhibrx (INBX), Black Diamond Therapeutics (BDTX), Aligos Therapeutics (ALGS), Cortexyme (CRTX), Cellectis (CLLS) and Adaptimmune Therapeutics (ADAP).
View all of AVRO's competitors.

What other stocks do shareholders of AVROBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVROBIO investors own include Sorrento Therapeutics (SRNE), ImmunoGen (imgn), Aduro Biotech (ADRO), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Biohaven Pharmaceutical (BHVN), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB), VBI Vaccines (vbiv) and Arbutus Biopharma (ABUS).

When did AVROBIO IPO?

(AVRO) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager.

What is AVROBIO's stock symbol?

AVROBIO trades on the NASDAQ under the ticker symbol "AVRO."

Who are AVROBIO's major shareholders?

AVROBIO's stock is owned by many different institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (12.36%), BlackRock Inc. (8.88%), Federated Hermes Inc. (3.44%), SV Health Investors LLC (3.27%), Emerald Advisers LLC (2.77%) and Emerald Mutual Fund Advisers Trust (2.56%). Company insiders that own AVROBIO stock include Bruce Booth, Christopher Paige and Geoffrey Mackay.
View institutional ownership trends for AVROBIO.

Which institutional investors are selling AVROBIO stock?

AVRO stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Dimensional Fund Advisors LP, SV Health Investors LLC, Victory Capital Management Inc., Squarepoint Ops LLC, State of Wisconsin Investment Board, and Monarch Partners Asset Management LLC.
View insider buying and selling activity for AVROBIO or view top insider-selling stocks.

Which institutional investors are buying AVROBIO stock?

AVRO stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., BlackRock Inc., Federated Hermes Inc., MPM Oncology Impact Management LP, Emerald Mutual Fund Advisers Trust, Morgan Stanley, Emerald Advisers LLC, and Kennedy Capital Management Inc..
View insider buying and selling activity for AVROBIO or or view top insider-buying stocks.

How do I buy shares of AVROBIO?

Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AVROBIO's stock price today?

One share of AVRO stock can currently be purchased for approximately $10.98.

How much money does AVROBIO make?

AVROBIO has a market capitalization of $400.23 million. The company earns $-72,960,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis.

How many employees does AVROBIO have?

AVROBIO employs 123 workers across the globe.

What is AVROBIO's official website?

The official website for AVROBIO is www.avrobio.com.

Where are AVROBIO's headquarters?

AVROBIO is headquartered at ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139.

How can I contact AVROBIO?

AVROBIO's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected]


This page was last updated on 2/25/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.